ArticleClinicoEconomics and outcomes research : CEOR2021
Erratum: Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum].
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.